HLA-DR BINDING PEPTIDES AND THEIR USES
The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines.
1 . (canceled)
2 . A method for eliciting an immune response to a tumor antigen within a mammal, wherein said method comprises administering a vaccine composition to said mammal, wherein said vaccine composition comprises an adjuvant and an isolated HLA-DR binding peptide having the sequence set forth in SEQ ID NO:145, and further comprises at least one additional peptide having the sequence set forth in SEQ ID NO:89 or SEQ ID NO:90.
3 . The method of claim 2 , wherein said mammal is a human.
4 . The method of claim 2 , wherein said vaccine composition further comprises a HTL-inducing peptide.
5 . The method of claim 2 , wherein said vaccine composition further comprises a CTL peptide.
6 . The method of claim 2 , wherein said vaccine composition further comprises a lipid.
7 . The method of claim 2 , wherein said vaccine composition further comprises a liposome.
8 . The method of claim 2 , wherein said vaccine composition further comprises at least two Carcinoembryonic Antigen (CEA) HTL peptides, at least two Cyclin D1 HTL peptides, and at least two Insulin Growth Factor Binding Protein 2 (IGFBP-2) HTL peptides.
9 . The method of claim 1 , wherein said at least one additional peptide has the sequence set forth in SEQ ID NO:89.
10 . The method of claim 1 , wherein said at least one additional peptide has the sequence set forth in SEQ ID NO:90.